Ropivacaine Though Laterosternal Catheters After Cardiac Surgery
- Conditions
- Cardiac Surgery
- Interventions
- Registration Number
- NCT01196767
- Lead Sponsor
- University Hospital, Clermont-Ferrand
- Brief Summary
This is a prospective double-blinded and randomised study involving patients undergoing cardiac surgery with median sternotomy, the effects on postoperative analgesia of a 48-hr continuous infusion of ropivacaine 2 mg.mL-1, at the rate of 4 mL.hr-1 through two catheters inserted at the lateral edges of the sternum will be studied, versus a control group in which normal saline will be infused in the same conditions.
- Detailed Description
Diverse methods for infusion of local anaesthetics after cardiac surgery have been proposed, but none of them provided high-level evidence of efficacy. The catheters studied here are designed for a surgical insertion before closure of the sternotomy, with the aim of infusing the drug the closest possible of the terminations of intercostal nerves.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 40
- Scheduled cardiac surgery.
-
- surgery in emergency
- thoracotomy
- cardiac graft
- redo
- pregnancy
- patient's refusal
- minor or adult under legal protection
- psychiatric ongoing disease
- addiction to opiates
- ongoing opiate treatment
- inability to use a PCA device
- respiratory insuffiency (Vital capacity or maximal expired volume per sec. < 50% of the expected value, or mean PAP > 50 mmHg)
- intra-aortic balloon
- severe renal insuffiency
- history of allergy or intolerance to: morphine, acetaminophen, bupivacaine.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description ropivacaine Ropivacaine (in one arm); catheterization (in both). - normal saline Ropivacaine (in one arm); catheterization (in both). -
- Primary Outcome Measures
Name Time Method Pain score at mobilization (lying position for measurement of central venous pressure), expressed on a visual analogue scale. every 4 hours during 48 hours
- Secondary Outcome Measures
Name Time Method Number of participants with adverse events daily during 48 hours nausea and vomiting, pruritus
Postoperative blood level of ropivacaine at day + 1 and day + 2 daily during 48 hours Pain score at rest, expressed on a visual analogue scale. every 4 hours during 48 hours Arterial blood gases every 4 hours during 48 hours Postoperative blood level of troponin every 8 hours during 48 hours Time to first flatus daily during 48 hours Morphine consumption on PCA device every 4 hours during 48 hours Vital capacity and inspiratory reserve volume, related to the preoperative values daily during 48 hours Signs of intoxication to ropivacaine eventual reports
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
CHU Clermont-Ferrand
🇫🇷Clermont-Ferrand, France
CHU Clermont-Ferrand🇫🇷Clermont-Ferrand, France